Deferasirox is an iron chelator and the first oral medication FDA approved for chronic iron overload in patients receiving long term blood transfusions.
Synonyms
Deferasirox
Deferasiroxum
Brand Names
Deferasirox (type J)
Exjade
Deferasirox Accord
Deferasirox
PMS-deferasirox (type J)
Jadenu
Auro-deferasirox (type J)
PMS-deferasirox
Taro-deferasirox (type J)
Teva-deferasirox
Apo-deferasirox (type J)
Taro-deferasirox
Deferasorox
Deferasirox Mylan
Apo-deferasirox
Deferasirox Oral Granules
Jamp Deferasirox (type J)
Sandoz Deferasirox (type J)
Teva-deferasirox (type J)
Deferasirox oral
Sandoz Deferasirox
Indication
For the treatment of chronic iron overload due to blood transfusions (transfusional hemosiderosis) in patients 2 years of age and older.
Categories
Acids, Carbocyclic
Benzene Derivatives
Benzoates
Chelating Agents
Compounds used in a research, industrial, or household setting
Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison
T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS.
Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682